Skip to content
Yondelis(trabectedin)
Yondelis (trabectedin) is a small molecule pharmaceutical. Trabectedin was first approved as Yondelis on 2007-09-17. It is used to treat leiomyosarcoma and liposarcoma in the USA. It has been approved in Europe to treat ovarian neoplasms and sarcoma. It is known to target nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Yondelis
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trabectedin
Tradename
Company
Number
Date
Products
YONDELISJohnson & JohnsonN-207953 RX2015-10-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
yondelisNew Drug Application2020-09-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
leiomyosarcoma—D007890—
liposarcoma—D008080—
Agency Specific
FDA
EMA
Expiration
Code
TRABECTEDIN, YONDELIS, JANSSEN PRODS
2023-04-23PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Trabectedin, Yondelis, Janssen Prods
88955572028-01-07DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01C: Plant alkaloids and other natural products, antineoplastic drugs
— L01CX: Other plant alkaloids and natural products in atc
— L01CX01: Trabectedin
HCPCS
Code
Description
J9352
Injection, trabectedin, 0.1 mg
Clinical
Clinical Trials
90 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C561451314
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD0125097196—735
LeiomyosarcomaD007890494——14
LiposarcomaD008080352——8
Fallopian tube neoplasmsD005185—11——2
Synovial sarcomaD013584——1—12
Peritoneal neoplasmsD010534——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8053———8
Myxoid liposarcomaD01820814———4
Ewing sarcomaD012512EFO_000017311——13
Ovarian epithelial carcinomaD000077216—1——12
Malignant mesotheliomaD000086002—2———2
Neoplasm metastasisD009362EFO_000970821———2
Breast neoplasmsD001943EFO_0003869C50—2———2
Endometrial neoplasmsD016889EFO_0004230—2———2
Neoplasms by siteD009371—2———2
RhabdomyosarcomaD012208—1——12
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatic insufficiencyD0485501————1
Neoplasms by histologic typeD0093701————1
Connective and soft tissue neoplasmsD0182041————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Desmoplastic small round cell tumorD058405————11
HemangioendotheliomaD006390————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRABECTEDIN
INNtrabectedin
Description
Trabectedin is a tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer. It has a role as an antineoplastic agent, a marine metabolite, an anti-inflammatory agent, an angiogenesis modulating agent and an alkylating agent. It is an organic heteropolycyclic compound, an azaspiro compound, an oxaspiro compound, a bridged compound, a lactone, a polyphenol, an acetate ester, a hemiaminal, an organic sulfide, a tertiary amino compound and an isoquinoline alkaloid.
Classification
Small molecule
Drug classecteinascidin derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4
Identifiers
PDB—
CAS-ID114899-77-3
RxCUI1716278
ChEMBL IDCHEMBL450449
ChEBI ID84050
PubChem CID108150
DrugBankDB05109
UNII IDID0YZQ2TCP (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
8856
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Q9UNW4
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,301 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
362 adverse events reported
View more details